Register Update: Während unserer Ferienzeit (17. Dezember - 4. Januar) wird es eine Verzögerung beim Hinzufügen neuer Datensätze geben
Cochrane COVID-19 Studienregister
Studienbericht
ChiCTR2100051956Erstmals veröffentlicht: 2022 Jan 28Letzte Aktualisierung: 2022 Jan 28

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in people living with HIV

  1. Studientyp
  2. Other
  1. Studienziel
  2. Prevention
  1. Studiendesign
  2. Case series/Case control/Cohort
  1. Interventionszuordnung
  2. Not Applicable
Referenzdatensätze

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in people living with HIV

ChiCTR2100051956
Eintrag in Studienregister
Keine Ergebnisse
INTERVENTION: PLWH group vs. Healthy control group:Nil; CONDITION: SARS-CoV-2 vaccine PRIMARY OUTCOME: age; sex; high; weight; therapy duration; CD4 counts; CD8 counts; HIV RNA level; SARS-CoV-2 IgG level; SARS-CoV-2 IgM level; Neutralizing antibody; SECONDARY OUTCOME: alanine aminotransferase; aspartate aminotransferase; albumin; globulin; platelets; lymphocytes; syphilis antibody; tuberculosis; hepatitis B surface antigen; INCLUSION CRITERIA: 1.PLWH group: (1) Aged above 18 years old; (2) Outpatient department of Nanfang Hospital from January 21, 2019 to September 21, 2019; (3) The diagnosis of HIV was based on the Guidance of Chinese AIDS Diagnosis and Treatment Guidelines (2018 edition); (4) At the time of visit, two doses of SARS-COV-2 inactivated vaccine had been given for more than 5 days; (5) Agreed to join the study and signed the informed consent. 2.Healthy control group: (1) Aged above 18 years old; (2) Outpatient department of Nanfang Hospital from January 21, 2019 to September 21, 2019; (3) HIV antibody negative; (4) At the time of visit, two doses of SARS-COV-2 inactivated vaccine had been given for more than 5 days; (5) Agreed to join the study and signed the informed consent